心不全 と がん の 関係: 背景 の 証拠 と 研究 展望
Edoardo Bertero1,2, Marco Canepa1, Christoph Maack2
1Cardiovascular Disease Unit, Ospedale Policlinico San Martino IRCCS & Laboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (E.B., M.C., P.A.).
Circulation
|October 26, 2018
まとめ
心不全 (HF) は,同時発生と検出バイアスの懸念にもかかわらず,癌のリスクを増やす可能性があります. 生物学的証拠は,HFが腫瘍性疾患である可能性を示唆し,この関連性に関するさらなる研究を促しています.
科学分野:
- 心臓病科
- 腫瘍学
- 翻訳研究
背景:
- 流行病学的な研究は,心不全 (HF) の患者でがんの発生率が高いことを示唆しています.
- 反対論点には,両疾患の高い罹患率と,HF患者における強化された医療監視による腫瘍検出の増加が含まれています.
- 新興の生物学的データは,HF自体が腫瘍性疾患である可能性があるという仮説を支持する.
研究 の 目的:
- 心不全 (HF) と癌の関連性を調べる
- HFが癌の診断の増加と関連していることを示唆する新しい証拠に照らして,既存の生物学的データを再評価する.
- HFと悪性腫瘍を結びつける潜在的な生物学的経路を調査する.
主な方法:
- 既存の疫学および生物学的研究のレビューと再評価.
- 低度の炎症などの全身的要因を考慮する.
- 腫瘍の成長に対するHFの影響を示す動物モデルへの参照
主要な成果:
- 以前は癌と関連していた神経ホルモンの活性化は,今ではHFの文脈で検討されています.
- 低度の炎症を特徴とする システム環境の混乱は,HFと癌の両方に寄与する可能性があります.
- 動物実験では 発血後のHFが 腫瘍の成長を促すことが示されています
結論:
- 心不全と癌の関連性は 新興的で重要な研究分野です
- 心不全ががんの発症を積極的に促進するかどうかを判断するには,さらなる調査が必要である.
- これらの関連性を理解すると 患者のケアや将来の研究方向に 影響を及ぼす可能性があります
関連する概念動画
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319